- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
- 10-Q Quarterly report
- 10.5 Director Compensation Policy
- 10.6 Master Services Agreement Dated July 9, 2012
- 10.7 Letter of Guarantee Between Registrant and Quintiles Commerical Europe Limited
- 15 Letter Regarding Unaudited Interim Financial Information
- 31.1 Section 302 CEO Certification
- 31.2 Section 302 CFO Certification
- 32 Section 906 CEO and CFO Certification
Exhibit No. 15
August 2, 2012
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Commissioners:
We are aware that our report dated August 2, 2012 on our review of interim financial information of Cell Therapeutics, Inc. for the six month period ended June 30, 2012 included in the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2012 is incorporated by reference in the Registration Statements of Cell Therapeutics, Inc. on Forms S-3 (File Nos. 333-130411, 333-131533, 333-130004, 333-36038, 333-41300, 333-67906, 333-36603, 333-38431, 333-108926, 333-112681, 333-138170, 333-134126, 333-143452, 333-149980, 333-149981, 333-149982, 333-152171, 333-160969, 333-158272, 333-157376, 333-153358, 333-163479, 333-161442, 333-93835, 333-33872, 333-33268, 333-39385, 333-177506 and 333-182330) and on Form S-8 (File No. 333-65200, 333-58957, 333-35919, 333-97015, 333-106568, 333-106571, 333-112791, 333-118016, 333-146624, 333-152168, 333-158260, 333-162955, 333-170044 and 333-178158).
Yours very truly,
/s/ Marcum LLP
San Francisco, California